This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-11. Anything still debated is marked as such rather than presented as settled.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
===== MeSH D08.811.399.520 – intramolecular transferases (EC 5.4) ===== MeSH D08.811.399.520.100 – 2-acetolactate mutase MeSH D08.811.399.520.250 – chorismate mutase MeSH D08.811.399.520.250.500 – prephenate dehydratase MeSH D08.811.399.520.250.750 – prephenate dehydrogenase MeSH D08.811.399.520.625 – methylmalonyl-coa mutase MeSH D08.811.399.520.750 – phosphotransferases (phosphomutases) MeSH D08.811.399.520.750.250 – bisphosphoglycerate mutase MeSH D08.811.399.520.750.625 – phosphoglucomutase MeSH D08.811.399.520.750.700 – phosphoglycerate mutase
He also places a massive £300 million long position on pound sterling, gambling that a rumored UK tax cut will raise the value of the pound. When the tax cut is realised, it has the opposite effect, putting Rishi at risk of booking millions in losses. After a disastrous casino binge, Diana agrees to cover his debts—only for Rishi’s long position to suddenly net £18 million when the tax cut is reversed alongside a significant increase in the pound interest rate. this success, however, prompts him to immediately take out another gambling loan. When Pierpoint’s stock collapses on its 150th anniversary, Rishi correctly deduces an acquisition after spotting the Barclays CEO enter the building. He interviews with Harper for a hedge fund role, only find that the job offer is a sham designed to humiliate him in front of Sweetpea and Anraj, who she has hired. On Rishi's birthday, Vinay tells Diana about Rishi’s debts and murders her in front of him, leaving Rishi traumatized. In series 4, Rishi is without a job, as he is unable to clear even basic background checks due to his wife's murder, and is revealed to have attempted suicide while living in a motel and abusing prescription drugs. Harper, who paid for his stay in rehab, gives him cash payments to surreptitiously obtain information that would aid her in shorting companies. Harper later cuts ties with Rishi after hiring Sweetpea, who is repulsed by him and refuses to work with Harper if he is involved.
In 2006, sales of Guinness in Ireland and the United Kingdom declined 7 percent. Despite this, Guinness still accounts for more than a quarter of all beer sold in Ireland. By 2015, sales were on the rise in Ireland but flat globally. By 2023, Guinness had grown to become the most popular draught beer in the United Kingdom, with about 11% of all sales. Guinness began retailing in India in 2007. Guinness has a significant share of the African beer market, where it has been sold since 1827. About 40 percent of worldwide total Guinness volume is brewed and sold in Africa, with Foreign Extra Stout the most popular variant. Three of the five Guinness-owned breweries worldwide are located in Africa. The beer is brewed under licence internationally in several countries, including Nigeria, the Bahamas, Canada, Cameroon, Kenya, Uganda, South Korea, Namibia, and Indonesia. In 2017, Guinness teamed up with AB InBev to distribute Guinness in mainland China. China is the single biggest worldwide alcohol market, especially for imported craft beers like Guinness. In 2025, AB InBev started brewing Guinness under licence in China. Initial reception was not favourable, with one publican reportedly stating that the "feedback from everyone is that it tastes like cigarettes or an ashtray. The taste is not the same at all and the aftertaste is terrible". In November 2025, Diego announced a "double-digit" decline in sales in China. The United Kingdom is the only sovereign state to consume more Guinness than Ireland.
==== Transhuman forces ==== The transhuman forces is the primary Combine military ground force on Earth. It consists of biomechanically enhanced humans who wear heavy body armor and gas masks. They are armed variously with submachine guns, shotguns, sniper rifles, and pulse rifles. The markings on their uniforms suggest a difference in specialization. Elite soldiers wear bright white armor with one-eyed helmets and can fire a ball of energy from their pulse rifle, while the rank-and-file wear blue, depending on their role as infantry or a shotgunner respectively. Soldiers wielding shotguns wear similar outfits to other transhuman soldiers but are equipped with uniforms coloured brown and helmets with orange (instead of blue) eyes. Overwatch soldiers typically operate in small groups of four to six using infantry tactics and grenades to flush out and flank the player. They occasionally provide support to Combine synths, and often travel to areas by use of dropships and armoured personnel carriers. Transhuman soldiers utilize two-way radios to communicate with each other and with headquarters. The transhuman forces are usually encountered outside City 17, and only appear in the city near the end of the game. They are commanded by the Overwatch, an unencountered artificial female voice which issues orders such as, "Attention ground units. Mission failure will result in permanent off-world assignment. Code reminder: sacrifice, coagulate, clamp."
When herbivores are moved around leaves of wild type plants, they reach similar masses to herbivores that consume only mutant plants, implying the effects of JAs are localized to sites of herbivory. Studies have shown that there is significant crosstalk between defense pathways.
Sources: en.wikipedia.org
is a physical property and defined as the optical rotation α at a path length l of 1 dm, a concentration c of 10 g/L, a temperature T (usually 20 °C) and a light wavelength λ (usually sodium D line at 589.3 nm):
A mammary gland is a specific type of apocrine gland specialized for manufacture of colostrum (first milk) when giving birth. Mammary glands can be identified as apocrine because they exhibit striking "decapitation" secretion. Many sources assert that mammary glands are modified sweat glands.
They feature multiply charged ions alkali metal adducts and non covalent complexes that originate from the condensed phase of the sample/solvent interaction. DESI is revealed to have a more gentle ionization condition that leads to a more pronounced tendency for metal adduct formation and a lower specific charging of secondary droplets.
Cohen (1952), former co-owner of the Boston Celtics and the Brooklyn Nets; former chairman and CEO of the Madison Square Garden Corporation Lawrence K. Grossman (1952), president of PBS 1976–1984 and NBC News 1985–1988 Richard Wald (1952), former president of NBC News 1973–1977 Robert A. Belfer (1955), oilman and philanthropist, namesake of the Belfer Center for Science and International Affairs at Harvard University Thomas Ludlow Chrystie II (1955), first chief financial officer of Merrill Lynch & Company and creator of the Cash Management Account Alfred Lerner (1955), chairman of MBNA Bank and ex-owner of the Cleveland Browns Richard Ravitch (1955), chairman of the Metropolitan Transportation Authority and the Bowery Savings Bank Sid Sheinberg (1955), head of Universal Pictures Barry F. Sullivan (1955), chairman and CEO of First Chicago Bank, deputy mayor of New York City under David Dinkins Edward Botwinick (1956), IT entrepreneur and inventor, co-founder of Timeplex Franklin A. Thomas (1956), former president of The Ford Foundation James R. Barker (1957), chairman of Interlake Steamship Company, former chairman and CEO of Moore-McCormack Peter L.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.